The prognostic value of monitoring early alterations in ABCB1 mRNA expression levels in CML patient cells in order to predict patient response to imatinib has recently been described[6]. This evidence concerns the gene ABCB1 and chronic myelogenous leukemia, BCR-ABL1 positive.